Saratov JOURNAL of Medical and Scientific Research
Home

Polymorphisms of hemostasis and folate cycle genes as predictors of COVID-19 severity

Year: 2025, volume 21 Issue: №2 Pages: 161-167
Heading: Cardiology Article type: Original article
Authors: Derisheva D.A., Yakhontov D.A., Lukinov V.L., Agletdinov E.F.
Organization: Institute of Computational Mathematics and Mathematical Geophysics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia, Novosibirsk State University, Vector-Best JSC, Novosibirsk, Russia
Summary:

Objective: to reveal the frequency of hemostasis and folate cycle gene polymorphisms in stable coronary heart disease (CHD) patients based on the severity of COVID-19 during the acute phase. Material and methods. During the study, 416 patients with stable CHD who had previously experienced COVID-19 with documented severity were examined for hemostasis and folate cycle gene polymorphisms. The severity of COVID-19 was used to categorize patients into two groups: the first group included patients with mild cases (n=203), while the second group comprised patients with moderate severity (n=213). The evaluation included the following genetic variants: 20210 G>A of the F2 gene, 1691 G>A of the F5 gene, 807 ОТ of the ITGA2 gene, 10976 G>A of the F7 gene, 1298 A>C of the MTHFR gene, 66 A>G of the MTRR gene, 2756 A>G of the MTR gene, 677 ОТ of the MTHFR gene, 455 G>Aof the FGB gene, 103 G>T of the F13A1 gene, 6755G>4G of the SERPINE1 (PAI-1) gene, and 1565 T>C of the ITGB3 gene. These polymorphisms likely contribute to a more severe course of COVID-19 in patients with CHD. Results. The presence of the heterozygous FGB: 455 G>A polymorphism and the ITGB3: 1565 T>C CC genotype may contribute to more severe COVID-19 progression in patients with CHD. Conversely, the CC genotype of the 807 ОТ polymorphism of the ITGA2 gene was associated with protection against more severe forms of the disease in the analyzed sample. Conclusion. Polymorphisms 455 G>Aof the FGB gene and 1565 T>C of the ITGB3 gene can be considered potential markers for detecting and predicting a more severe course of COVID-19 in patients with CHD.

Keywords: coronary heart diseases, COVID-19, folate cycle genes, hemostasis genes, post-COVID period

Bibliography:
1. George РМ, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020;75 (11):1009-16. DOI:10.1136/thoraxjnl-2020-215314
2. Lippi G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): The portrait of a perfect storm. Ann Transl Med. 2020;8(7):497. DOI:10.21037/atm.2020.03.157
3. Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021 ;97(1147):312-20. DOM0.1136/postgradmedj-2020-138577
4. Liu H, Wang Z, Sun H, et al. Thrombosis and coagu-lopathy in COVID-19: Current understanding and implications for antithrombotic treatment in patients treated with percutaneous coronary intervention. Front Cardiovasc Med. 2021 ;7:599334. DOI:10.3389/fcvm. 2020.599334
5. Attaway AH, Scheraga RG, Bhimraj A, et al. Severe COVID-19 pneumonia: Pathogenesis and clinical management. BMJ. 2021 ;372:n436. DOI:10.1136/bmj.n436
6. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute CO-VID-19 syndrome. Nat Med. 2021;27:601-15. DOI:10.1038/s41 591-021-01283-z
7. Maria BL, Prosperi S, Sara M, et al. Follow-up of hospitalized COVID-19 survivors: Assessment OF short and long-term cardiovascular sequelae after SARS-COV-2 infection. J Am Coll Cardiol. 2022;79(9):2157. DOI:10.1016/S0735-1097(22)03148-5
8. Farshidfar F, Koleini N, Ardehali H. Cardiovascular complications of COVID-19. JCI Insight. 2021 ;6(13):e148980. DOI:10.1172/jci.insight.148980
9. Delanghe JR, Speeckaert MM, De Buyzere ML. COVID-19 infections are also affected by human ACE1 D/l polymorphism. Clin Chem Lab Med. 2020;58(7):1125-6. DOI:10.1515/cclm-2020-0425
10. Gomez J, Albaiceta GM, Garcia-Clemente M, et al. Angiotensin-converting enzymes (АСЕ, ACE2) gene variants and COVID-19 outcome. Gene. 2020;762:145102. DOI:10.1016/j.gene.2020.145102
11. Deng H, Yan X, Yuan L. Human genetic basis of coronavirus disease 2019. Signal Transduct Target Ther. 2021 ;6 (1):344. DOI:10.1038/s41392-021-00736-8
12. Wang W, Zhang W, Zhang J, et al. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19). HLA. 2020;96(2):194-6. DOI:10.1111/tan.13941
13. Ponti G, Pastorino L, Manfredini M, et al. COVID-19 spreading across world correlates with C677T allele of the methylenetetrahydrofolate reductase (MTHFR) gene prevalence. J Clin Lab Anal. 2021 ;35(7):e23798. DOI:10.1002/jcla.23798
14. Zhang Q, Jin Y, Li X, et al. Plasminogen activator inhibi-tor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism — A meta-analysis and systematic review. Vasa. 2020;49(2):141-6. DOI:10.1024/0301-1526/a000839
15. Yatsenko T, Rios R, Nogueira T, et al. The influence of 4G/5G polymorphism in the plasminogen-activator-inhibi-tor-1 promoter on COVID-19 severity and endothelial dysfunction. Front Immunol. 2024;15:1445294. DOI:10.3389/fimmu.2024.1445294
16. Nikolaeva LI, Stuchinskaya MD, Dedova AV, et al. Association of polymorphic variants of hemostatic system genes with the course of COVID-19. Problems of Virology. 2023;68 (5):445-53. DOI:10.36233/0507-4088-197
17. Ye Q, Wang В, Mao J. The pathogenesis and treatment of the Xytokine Storm' in COVID-19. J Infect. 2020;80(6):607-13. DOI:10.1016/j.jinf.2020.03.037
18. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181 (2):271-80.e8. DOI:10.1016/j.cell.2020.02.052
19. Martiskainen M, Oksala N, Pohjasvaara T, et al. Beta-fibrinogen gene promoter A -455 allele associated with poor longterm survival among 55-71 years old Caucasian women in Finnish stroke cohort. ВМС Neurol. 2014;14:137. DOI:10.1186/1471-2377-14-137
20. Sypniewski M, Krol ZJ, Szyda J, et al. Gene variants related to cardiovascular and pulmonary diseases may correlate with severe outcome of COVID-19. Int J Mol Sci. 2022;23 (15):8696. DOI:10.3390/ijms23158696

AttachmentSize
2025_02_161-167.pdf382.98 KB
All articles of the authors: Agletdinov E.F. , Derisheva D.A., Lukinov V.L., Yakhontov D.A.

No votes yet